HYRIMOZ

Sandoz Inc🇺🇸 United States

FDA Page

Effective Date: Oct 17, 2025
Approval ID: 1ac7d061-3380-468c-b077-c05f8dfbc829
Products: 6 registered
Version: 14

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use HYRIMOZ safely and effectively. See full prescribing information for HYRIMOZ. HYRIMOZ (adalimumab-adaz) injection, for subcutaneous useInitial U.S. Approval: 2018HYRIMOZ (adalimumab-adaz) is biosimilar* to HUMIRA (adalimumab)

Quick Stats

Total Products6

Labelers2

Label Sections33

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.